Between Jan @ , @ , and Sept @ , @ , we randomly allocated @ participants ; @ received epirubicin and cyclophosphamide then paclitaxel ; @ were given paclitaxel then epirubicin and cyclophosphamide ; @ had epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ; and @ received paclitaxel and gemcitabine then epirubicin and cyclophosphamide .